Expertise in
8
conditions

Dr. Kimberly L. Blackwell

Hematology | Oncology
Duke University Health System Inc
20 Duke Medicine Cir, 
Durham, NC 
Expertise in
8
conditions
Duke University Health System Inc
20 Duke Medicine Cir, 
Durham, NC 

Overview

Kimberly Blackwell is a Hematologist and an Oncologist practicing medicine in Durham, North Carolina.

Dr. Blackwell is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Agranulocytosis, and Paget Disease of the Breast.

She is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Duke University Health System Inc
20 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
Enrollment Status: Completed
Publish Date: January 23, 2026
Intervention Type: Drug, Procedure
Study Drugs: HKI-272, Capecitabine, Ado-Trastuzumab Emtansine
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Olaparib, durvalumab
Study Phase: Phase 2
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 17, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Enrollment Status: Terminated
Publish Date: February 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2018
View 9 Less Clinical Trials

73 Total Publications

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026
Similar Doctors
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Referral may be required

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (5.6 miles away)
984-974-2695
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist and an Oncologist practicing medicine in Chapel Hill, North Carolina. Dr. Key is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease. Dr. Key is currently accepting new patients.

Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Referral may be required

Duke University Hospital

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-668-6288
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist and an Oncologist practicing medicine in Durham, North Carolina. Dr. Ashley is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Expertise in
20
conditions
Dr. Lars M. Wagner
Hematology | Oncology
Expertise in
20
conditions
Dr. Lars M. Wagner
Hematology | Oncology
Referral may be required

Duke University Hospital

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-3772
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lars Wagner is a Hematologist and an Oncologist practicing medicine in Durham, North Carolina. Dr. Wagner is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration. Dr. Wagner is currently accepting new patients.

Frequently Asked Questions about Dr. Kimberly L. Blackwell

How do I make an appointment with Dr. Kimberly L. Blackwell?

You can book an appointment with Dr. Kimberly L. Blackwell by calling their office at 919-668-1748. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kimberly L. Blackwell a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kimberly L. Blackwell is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kimberly L. Blackwell specialize in?

While Dr. Kimberly L. Blackwell is a Hematology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kimberly L. Blackwell participate in research or clinical trials?

Yes. Dr. Kimberly L. Blackwell has published 73 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Kimberly L. Blackwell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blackwell's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile